The general objective and overall goal of the project is to understand the molecular mechanisms in melanoma cells which induce changes in the immunological properties leading to progression of disease, and to develop a platform for generation of novel prognostic and therapeutic tools. We have compiled the consortium of six partners from Estonia to cover all required areas of expertise for this project. Our interdisciplinary project brings together medical doctors, scientists and research groups from different institutes. Of special value of our project is that the ideology and hypothesis for this project has derived from clinical problems described by doctors in their practice. All methods which are required in this project will be covered by skills and expertise and specific infrastructure of partners of this consortium. The added value for the clinical members of the research group is the exchange of ideas with scientists competent in molecular biology and technologies. The clinicians treat patients using clinically proven evidence based solutions, however the access to novel basic scientific information and techniques and application of these to everyday practice is limited. On the other hand the research scientists may generate many potentially clinically relevant findings, but these results are often not translated into clinical care and management. Therefore, in our project, the clinicians participate actively in defining the objectives of the project, in describing clinical obstacles and finding solutions, which guarantees that basic research is carried out keeping in focus the ultimate goal of recovery from disease.
|SA Põhja-Eesti Regionaalhaigla||partner||Eesti Vabariik|
|Vähiuuringute Tehnoloogia Arenduskeskus AS||partner||Eesti Vabariik|
|Eesti Biokeskus||partner||Eesti Vabariik|
|Icosagen Cell Factory OÜ||partner||Eesti Vabariik|